Journal ArticleDOI
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
TLDR
A low rate of prostate cancer mortality was observed among the patients who were reclassified as higher risk and who were treated, PSA failure was relatively common and other-cause mortality accounted for almost all of the deaths.Abstract:
Purpose We assessed the outcome of a watchful-waiting protocol with selective delayed intervention by using clinical prostate-specific antigen (PSA), or histologic progression as treatment indications for clinically localized prostate cancer. Patients and Methods This was a prospective, single-arm, cohort study. Patients were managed with an initial expectant approach. Definitive intervention was offered to those patients with a PSA doubling time of less than 3 years, Gleason score progression (to 4 + 3 or greater), or unequivocal clinical progression. Survival analysis and Cox proportional hazard model were applied to the data. Results A total of 450 patients have been observed with active surveillance. Median follow-up was 6.8 years (range, 1 to 13 years). Overall survival was 78.6%. The 10-year prostate cancer actuarial survival was 97.2%. Overall, 30% of patients have been reclassified as higher risk and have been offered definitive therapy. Of 117 patients treated radically, the PSA failure rate was ...read more
Citations
More filters
Journal ArticleDOI
EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet,Joaquim Bellmunt,Michel Bolla,Erik Briers,Marcus G. Cumberbatch,Maria De Santis,Nicola Fossati,Tobias Gross,Ann Henry,Steven Joniau,Thomas B. Lam,Thomas B. Lam,Malcolm David Mason,Vsevolod Matveev,Paul C. Moldovan,Roderick C.N. van den Bergh,Thomas Van den Broeck,Henk G. van der Poel,Theo H. van der Kwast,Olivier Rouvière,Ivo G. Schoots,Thomas Wiegel,Philip Cornford +22 more
TL;DR: The 2016 EAU-STRO-IOG Prostate Cancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostate cancer and reflect the multidisciplinary nature of PCa management.
Journal ArticleDOI
Radical prostatectomy versus watchful waiting in early prostate cancer.
Anna Bill-Axelson,Anna Bill-Axelson,Lars Holmberg,Mirja Ruutu,Hans Garmo,Jennifer R. Stark,Jennifer R. Stark,Christer Busch,Stig Nordling,Michael Häggman,Swen-Olof Andersson,Stefan Bratell,Anders Spångberg,Juni Palmgren,Gunnar Steineck,Hans-Olov Adami,Hans-Olov Adami,Jan-Erik Johansson +17 more
TL;DR: Radical prostatectomy was associated with a reduction in the rate of death from prostate cancer, and men with extracapsular tumor growth may benefit from adjuvant local or systemic treatment.
Journal ArticleDOI
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
Axel Heidenreich,Patrick J. Bastian,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Theodor van der Kwast,Malcolm David Mason,Vsevolod Matveev,Thomas Wiegel,Filiberto Zattoni,Nicolas Mottet +10 more
TL;DR: Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa, and watchful waiting is a treatment alternative to androgen-deprivation therapy (ADT), with equivalent oncologic efficacy.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Axel Heidenreich,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Malcolm David Mason,Vsevolod Matveev,Nicolas Mottet,Hans-Peter Schmid,Theo van der Kwast,Thomas Wiegel,F. Zattoni +10 more
TL;DR: Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa, and these EAU guidelines on PCa summarise the most recent findings and put them into clinical practice.
References
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Natural History of Early, Localized Prostate Cancer
Jan-Erik Johansson,Ove Andrén,Swen Olof Andersson,Paul W. Dickman,Lars Holmberg,Anders Magnuson,Hans-Olov Adami +6 more
TL;DR: Although most prostate cancers diagnosed at an early stage have an indolent course, local tumor progression and aggressive metastatic disease may develop in the long term, and these findings would support early radical treatment, notably among patients with an estimated life expectancy exceeding 15 years.
Journal ArticleDOI
A Decision Analysis of Alternative Treatment Strategies for Clinically Localized Prostate Cancer
TL;DR: Radical prostatectomy and radiation therapy may benefit selected groups of patients with localized prostate cancer, particularly younger patients with higher-grade tumors, and watchful waiting is a reasonable alternative to invasive treatment for many men with localized prostatic carcinoma.
Journal ArticleDOI
Active Surveillance for Prostate Cancer: For Whom?
TL;DR: The approach to favorable-risk prostate cancer described in this article uses estimation of PSA doubling time (PSA DT) to stratify patients according to the risk of progression, and represents a practical compromise between radical therapy for all and watchful waiting with palliative therapy only.
Related Papers (5)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
Radical prostatectomy versus observation for localized prostate cancer.
Timothy J Wilt,Michael K. Brawer,Karen M. Jones,Michael J. Barry,William J. Aronson,Steven Fox,Jeffrey R. Gingrich,John T. Wei,Patricia Gilhooly,B. Mayer Grob,Imad Nsouli,Padmini Iyer,Ruben Cartagena,Glenn Snider,Claus G. Roehrborn,Roohollah Sharifi,William Blank,Parikshit Pandya,Gerald L. Andriole,Daniel J. Culkin,Thomas M. Wheeler +20 more